
Zephyr AI: Revolutionizing healthcare with innovative drug discovery and precision medicine tech.
Zephyr AI, founded with the mission to revolutionize healthcare, focuses on innovative drug discovery and precision medicine. Leveraging an AI-enabled platform, Zephyr AI utilizes vast and diverse healthcare and biological data to uncover hidden insights, match patients to drugs, and accelerate the development of new medications. Their technology aims to deliver robust, real-world efficacy in clinical settings, ensuring that every discovery reaches its full potential in patient care.
Notable figures affiliated with Zephyr AI include experts in healthcare technology and precision medicine. The company has attracted significant investment from leading venture capital firms specializing in biotech and AI. Key achievements include the successful implementation of their platform in clinical environments and partnerships with major healthcare institutions. Zephyr AI's impact lies in its ability to make drug discovery more efficient and patient-centric, ultimately transforming the landscape of precision medicine.

BioAI Health
bioaihealth.com

Pathos AI
pathos.com

Insitro
insitro.com

TandemAI
tandemai.com

Ariz Precision Medicine
arizbio.com

Ambit.AI
ambit.ai

DeepCure
deepcure.ai

Precision Health AI

Terray Therapeutics
terraytx.com

Cipherome
cipherome.com

Zymeron
zymeron.com

Phronesis Artificial Intelligence
phronesisai.com

Model Medicines
modelmedicines.com

Verge Genomics
vergegenomics.com

Insilico Medicine
insilico.com
Companies similar to Zephyr AI include BioAI Health, Pathos AI, Insitro and TandemAI.
Zephyr AI was founded in 2020.
Zephyr AI's headquarters is located in Dallas, TX, US.
Zephyr AI's most recent funding round was for $18.5M (USD) in March 2022.
As of Mar 30, 2022, Zephyr AI has raised a total of $18.5M (USD).
Zephyr AI has 47 employees as of Feb 5, 2024.